Christopher Maynard, MD
Internal Medicine · Athens, TNNPI 1750386819
Payments from drug & device makers
Across 114 payments — averaging $15.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$447
- GSK$225
- AbbVie$216
- Novartis$146
- Pfizer$136
- E.r. Squibb & Sons, L.L.C.$81
- plus $492 from 14 others
What the payments were for
- Food & beverage$1,743100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 37 | $447 |
| GSK | 12 | $225 |
| AbbVie | 14 | $216 |
| Novartis | 9 | $146 |
| Pfizer | 8 | $136 |
| E.r. Squibb & Sons, L.L.C. | 6 | $81 |
| Abbott | 4 | $71 |
| Novo Nordisk | 4 | $67 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $49 |
| Lilly USA, LLC | 3 | $47 |
| AstraZeneca | 3 | $44 |
| Johnson & Johnson | 2 | $32 |
| Dynavax Technologies Corporation | 1 | $29 |
| Exact Sciences | 2 | $29 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Nevro Corp. | 1 | $24 |
| Philips North America LLC | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Heartflow, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
How this compares
$1,743 in reported general payments places this provider in the 75th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 128 | $141,320 |
| JardianceEmpagliflozin | 81 | $79,651 |
| OzempicSemaglutide | 45 | $75,067 |
| TrulicityDulaglutide | 77 | $74,676 |
| XareltoRivaroxaban | 74 | $70,989 |
| MounjaroTirzepatide | 40 | $42,265 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $40,928 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 128 | $40,857 |
| FarxigaDapagliflozin Propanediol | 37 | $31,033 |
| GlyxambiEmpagliflozin/Linagliptin | 34 | $28,096 |
| Repatha SureclickEvolocumab | 28 | $27,738 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $22,148 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $20,981 |
| LinzessLinaclotide | 19 | $18,106 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 79 | $17,625 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $136 | $182,177256 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $47 | $116,941117 claims |
| Boehringer IngelheimJardiance, Glyxambi | $16 | $107,747115 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Anoro Ellipta | $225 | $88,669194 claims |
| Novo NordiskOzempic | $67 | $75,06745 claims |
| Johnson & JohnsonXarelto | $32 | $70,98974 claims |
| AstraZenecaFarxiga | $44 | $31,03337 claims |
| AbbVieLinzess, Synthroid | $216 | $20,91074 claims |
| NovartisEntresto | $146 | $14,05316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Athens
- Charles SharpeAthens$98K
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.